Publication:
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

dc.contributor.authorYasunori Watanabeen_US
dc.contributor.authorLuiza Mendonçaen_US
dc.contributor.authorElizabeth R. Allenen_US
dc.contributor.authorAndrew Hoween_US
dc.contributor.authorMercede Leeen_US
dc.contributor.authorJoel D. Allenen_US
dc.contributor.authorHimanshi Chawlaen_US
dc.contributor.authorDavid Pulidoen_US
dc.contributor.authorFrancesca Donnellanen_US
dc.contributor.authorHannah Daviesen_US
dc.contributor.authorMarta Ulaszewskaen_US
dc.contributor.authorSandra Belij-Rammerstorferen_US
dc.contributor.authorSusan Morrisen_US
dc.contributor.authorAnna Sophia Krebsen_US
dc.contributor.authorWanwisa Dejnirattisaien_US
dc.contributor.authorJuthathip Mongkolsapayaen_US
dc.contributor.authorPiyada Supasaen_US
dc.contributor.authorGavin R. Screatonen_US
dc.contributor.authorCatherine M. Greenen_US
dc.contributor.authorTeresa Lambeen_US
dc.contributor.authorPeijun Zhangen_US
dc.contributor.authorSarah C. Gilberten_US
dc.contributor.authorMax Crispinen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherNIHR Oxford Biomedical Research Centreen_US
dc.contributor.otherDiamond Light Sourceen_US
dc.contributor.otherThe Wellcome Centre for Human Geneticsen_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherUniversity of Southamptonen_US
dc.contributor.otherNuffield Department of Medicineen_US
dc.contributor.otherUniversity of Oxford Medical Sciences Divisionen_US
dc.date.accessioned2022-08-04T08:19:13Z
dc.date.available2022-08-04T08:19:13Z
dc.date.issued2021-04-28en_US
dc.description.abstractVaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.en_US
dc.identifier.citationACS Central Science. Vol.7, No.4 (2021), 594-602en_US
dc.identifier.doi10.1021/acscentsci.1c00080en_US
dc.identifier.issn23747951en_US
dc.identifier.issn23747943en_US
dc.identifier.other2-s2.0-85105109368en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/76537
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105109368&origin=inwarden_US
dc.subjectChemical Engineeringen_US
dc.subjectChemistryen_US
dc.titleNative-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccineen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105109368&origin=inwarden_US

Files

Collections